ABT-199: Taking Dead Aim at BCL-2

被引：74

作者：

Davids, Matthew S. ^{[1
]}

Letai, Anthony ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

来源：

CANCER CELL | 2013年 / 23卷 / 02期

关键词：

CHRONIC LYMPHOCYTIC-LEUKEMIA; FAMILY; ABT-737;

D O I：

10.1016/j.ccr.2013.01.018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ABT-199 is a new selective small molecule inhibitor of BCL-2 that appears to spare platelets while achieving potent antitumor activity. Assays that can predict the efficacy of ABT-199 in individual tumors will be critical in determining how best to incorporate this promising agent into the armamentarium of cancer therapies.

引用

页码：139 / 141

页数：3

共 10 条

[1] Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members
Certo, Michael
Moore, Victoria Del Gaizo
Nishino, Mari
Wei, Guo
Korsmeyer, Stanley
Armstrong, Scott A.
Letai, Anthony
[J]. CANCER CELL, 2006, 9 (05) : 351 - 365
[2] Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy
Chonghaile, Triona Ni
Sarosiek, Kristopher A.
Thanh-Trang Vo
Ryan, Jeremy A.
Tammareddi, Anupama
Moore, Victoria Del Gaizo
Deng, Jing
Anderson, Kenneth C.
Richardson, Paul
Tai, Yu-Tzu
Mitsiades, Constantine S.
Matulonis, Ursula A.
Drapkin, Ronny
Stone, Richard
DeAngelo, Daniel J.
McConkey, David J.
Sallan, Stephen E.
Silverman, Lewis
Hirsch, Michelle S.
Carrasco, Daniel Ruben
Letai, Anthony
[J]. SCIENCE, 2011, 334 (6059) : 1129 - 1133
[3] Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia
Davids, Matthew S.
Deng, Jing
Wiestner, Adrian
Lannutti, Brian J.
Wang, Lili
Wu, Catherine J.
Wilson, Wyndham H.
Brown, Jennifer R.
Letai, Anthony
[J]. BLOOD, 2012, 120 (17) : 3501 - 3509
[4] Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer
Davids, Matthew S.
Letai, Anthony
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (25) : 3127 - 3135
[5] BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents
Deng, Jing
Carlson, Nicole
Takeyama, Kunihiko
Dal Cin, Paola
Shipp, Margaret
Letai, Anthony
[J]. CANCER CELL, 2007, 12 (02) : 171 - 185
[6] Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737
Moore, Victoria Del Gaizo
Brown, Jennifer R.
Certo, Michael
Love, Tara M.
Novina, Carl D.
Letai, Anthony
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (01) : 112 - 121
[7] An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T
Elmore, SW
Shoemaker, AR
Armstrong, RC
Augeri, DJ
Belli, BA
Bruncko, M
Deckwerth, TL
Dinges, J
Hajduk, PJ
Joseph, MK
Kitada, S
Korsmeyer, SJ
Kunzer, AR
Letai, A
Li, C
Mitten, MJ
Nettesheim, DG
Ng, S
Nimmer, PM
O'Connor, JM
Oleksijew, A
Petros, AM
Reed, JC
Shen, W
Tahir, SK
Thompson, CB
Tomaselli, KJ
Wang, BL
Wendt, MD
Zhang, HC
Fesik, SW
Rosenberg, SH
[J]. NATURE, 2005, 435 (7042) : 677 - 681
[8] Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
Roberts, Andrew W.
Seymour, John F.
Brown, Jennifer R.
Wierda, William G.
Kipps, Thomas J.
Khaw, Seong Lin
Carney, Dennis A.
He, Simon Z.
Huang, David C. S.
Xiong, Hao
Cui, Yue
Busman, Todd A.
McKeegan, Evelyn M.
Krivoshik, Andrew P.
Enschede, Sari H.
Humerickhouse, Rod
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05) : 488 - 496
[9] Souers AJ, 2013, NAT MED
[10] Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML
Thanh-Trang Vo
Ryan, Jeremy
Carrasco, Ruben
Neuberg, Donna
Rossi, Derrick J.
Stone, Richard M.
DeAngelo, Daniel J.
Frattini, Mark G.
Letai, Anthony
[J]. CELL, 2012, 151 (02) : 344 - 355

← 1 →